BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30785356)

  • 1. Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study.
    Suzuki K; Kondo K; Washio M; Nakashima K; Kan S; Imai S; Yoshimura K; Ota C; Ohfuji S; Fukushima W; Hirota Y
    Hum Vaccin Immunother; 2019; 15(9):2171-2177. PubMed ID: 30785356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
    Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
    Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study.
    Kondo K; Suzuki K; Washio M; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
    Vaccine; 2017 Aug; 35(36):4806-4810. PubMed ID: 28818473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumococcal and influenza vaccination status of hospitalized adults with community acquired pneumonia and the effects of vaccination on clinical presentation.
    Demirdogen Cetinoglu E; Uzaslan E; Sayıner A; Cilli A; Kılınc O; Sakar Coskun A; Hazar A; Kokturk N; Filiz A; Polatli M;
    Hum Vaccin Immunother; 2017 Sep; 13(9):2072-2077. PubMed ID: 28708954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study.
    Heo JY; Seo YB; Choi WS; Kim EJ; Jeong HW; Lee J; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Song JY
    J Infect Dis; 2022 Mar; 225(5):836-845. PubMed ID: 34537847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of 23-Valent Pneumococcal Polysaccharide Vaccine Inoculated During Anti-Cancer Treatment Period in Elderly Lung Cancer Patients on Community-Acquired Pneumonia Hospitalization: A Nationwide Population-Based Cohort Study.
    Chiou WY; Hung SK; Lai CL; Lin HY; Su YC; Chen YC; Shen BJ; Chen LC; Tsai SJ; Lee MS; Li CY
    Medicine (Baltimore); 2015 Jul; 94(26):e1022. PubMed ID: 26131806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain.
    Domínguez À; Soldevila N; Toledo D; Torner N; Force L; Pérez MJ; Martín V; Rodríguez-Rojas L; Astray J; Egurrola M; Sanz F; Castilla J;
    PLoS One; 2017; 12(2):e0171943. PubMed ID: 28187206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations.
    Li Y; Zhang P; An Z; Yue C; Wang Y; Liu Y; Yuan X; Ma Y; Li K; Yin Z; Wang L; Wang H
    Respirology; 2022 Oct; 27(10):844-853. PubMed ID: 35705329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
    Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
    PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial.
    Huijts SM; Coenjaerts FEJ; Bolkenbaas M; van Werkhoven CH; Grobbee DE; Bonten MJM;
    Clin Microbiol Infect; 2018 Jul; 24(7):764-770. PubMed ID: 29050992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vaccination against community acquired pneumonia in adult patients. A position paper by Neumoexpertos en Prevención].
    Redondo E; Rivero I; Vargas DA; Mascarós E; Díaz-Maroto JL; Linares M; Valdepérez J; Gil A; Molina J; Jimeno I; Ocaña D; Martinón-Torres F;
    Semergen; 2016 Oct; 42(7):464-475. PubMed ID: 27641310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
    Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
    Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of pneumococcal vaccination among older adults with pneumonia: findings from the Community Acquired Pneumonia Impact Study.
    Krueger P; St Amant O; Loeb M
    BMC Geriatr; 2010 Jun; 10():44. PubMed ID: 20591180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan.
    Kawakami K; Ohkusa Y; Kuroki R; Tanaka T; Koyama K; Harada Y; Iwanaga K; Yamaryo T; Oishi K
    Vaccine; 2010 Oct; 28(43):7063-9. PubMed ID: 20723631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community-Acquired Pneumococcal Pneumonia in Highly Vaccinated Population: Analysis by Serotypes, Vaccination Status, and Underlying Medical Conditions.
    Hyun H; Jang AY; Suh JW; Bae IG; Choi WS; Seo YB; Lee J; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Kim MJ; Song JY
    J Korean Med Sci; 2023 Oct; 38(42):e330. PubMed ID: 37904655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
    Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
    Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons.
    Domínguez A; Castilla J; Godoy P; Delgado-Rodríguez M; Saez M; Soldevila N; Astray J; Mayoral JM; Martín V; Quintana JM; González-Candelas F; Galán JC; Tamames S; Castro A; Baricot M; Garín O; Pumarola T;
    Hum Vaccin Immunother; 2013 Apr; 9(4):865-73. PubMed ID: 23563516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of mortality and pneumonia among nursing home older adults by dual pneumococcal and seasonal influenza vaccination during a pandemic caused by novel pandemic influenza A (H1N1).
    Chan TC; Hung IF; Luk JK; Shea YF; Chan FH; Woo PC; Chu LW
    J Am Med Dir Assoc; 2012 Oct; 13(8):698-703. PubMed ID: 22722051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.
    McLaughlin JM; Jiang Q; Isturiz RE; Sings HL; Swerdlow DL; Gessner BD; Carrico RM; Peyrani P; Wiemken TL; Mattingly WA; Ramirez JA; Jodar L
    Clin Infect Dis; 2018 Oct; 67(10):1498-1506. PubMed ID: 29790925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
    Nakashima K; Aoshima M; Ohfuji S; Yamawaki S; Nemoto M; Hasegawa S; Noma S; Misawa M; Hosokawa N; Yaegashi M; Otsuka Y
    Hum Vaccin Immunother; 2018; 14(8):1923-1930. PubMed ID: 29561248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.